Nishijima T, Gatanaga H, Shimbo T, Komatsu H, Endo T, Horiba M, Koga M, Naito T, Itoda I, Tei M, Fujii T, Takada K, Yamamoto M, Miyakawa T, Tanabe Y, Mitsuya H, Oka S; SPARE study team.

Switching tenofovir/emtricitabine plus lopinavir/r to raltegravir plus Darunavir/r in patients with suppressed viral load did not result in improvement of renal function but could sustain viral suppression: a randomized multicenter trial.

PLoS One. 2013 Aug 8;8(8):e73639. doi: 10.1371/journal.pone.0073639. PMID: 23951362; PMCID: PMC3738570.

https://pubmed.ncbi.nlm.nih.gov/23951362/